4.6 Review

LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights

期刊

CELLS
卷 11, 期 1, 页码 -

出版社

MDPI
DOI: 10.3390/cells11010169

关键词

leucine-rich repeat kinase 2 (LRRK2); Parkinson's disease; striatum; synapse; cell-type specificity; protein kinase A (PKA); A-kinase adaptor protein (AKAP)

资金

  1. NINDS [NS097901]
  2. Michael J Fox Foundation for Parkinson's disease grant
  3. Aligning Science Across Parkinson's (ASAP) [020600]
  4. NIH [AG020506]

向作者/读者索取更多资源

Mutations in the LRRK2 gene can lead to Parkinson's disease with similar clinical presentation and progression to idiopathic Parkinson's disease, making it a valuable model for understanding the pathobiology of the disease. Studies suggest that pathogenic LRRK2 mutations disrupt synapses in striatal neurons, which has significant implications for the development of neurodegenerative diseases.
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease with a similar clinical presentation and progression to idiopathic Parkinson's disease, and common variation is linked to disease risk. Recapitulation of the genotype in rodent models causes abnormal dopamine release and increases the susceptibility of dopaminergic neurons to insults, making LRRK2 a valuable model for understanding the pathobiology of Parkinson's disease. It is also a promising druggable target with targeted therapies currently in development. LRRK2 mRNA and protein expression in the brain is highly variable across regions and cellular identities. A growing body of work has demonstrated that pathogenic LRRK2 mutations disrupt striatal synapses before the onset of overt neurodegeneration. Several substrates and interactors of LRRK2 have been identified to potentially mediate these pre-neurodegenerative changes in a cell-type-specific manner. This review discusses the effects of pathogenic LRRK2 mutations in striatal neurons, including cell-type-specific and pathway-specific alterations. It also highlights several LRRK2 effectors that could mediate the alterations to striatal function, including Rabs and protein kinase A. The lessons learned from improving our understanding of the pathogenic effects of LRRK2 mutations in striatal neurons will be applicable to both dissecting the cell-type specificity of LRRK2 function in the transcriptionally diverse subtypes of dopaminergic neurons and also increasing our understanding of basal ganglia development and biology. Finally, it will inform the development of therapeutics for Parkinson's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据